Navigation Links
Review Questions Tamiflu's Effectiveness
Date:12/8/2009

Finds no proof the drug prevents flu complications such as pneumonia

TUESDAY, Dec. 8 (HealthDay News) -- No evidence exists that the widely used influenza drug Tamiflu prevents pneumonia or other complications in otherwise healthy patients who come down with the flu, a new review contends.

Claims about the effectiveness of the antiviral drug against flu-related complications have influenced governments worldwide to stockpile Tamiflu (oseltamivir) as part of their preparations for a global pandemic, the review authors said.

"Governments around the world have spent billions of [dollars] on a drug that the scientific community now finds itself unable to judge," said Dr. Fiona Godlee, editor-in-chief of the British Medical Journal, which published the article online Wednesday. The review was done by BMJ and Channel 4 News in Great Britain.

The authors of the new review, which updates a review published in 2006, analyzed 20 published clinical trials of Tamiflu that examined prevention, treatment and adverse reactions. However, the analysis was hampered by the "paucity of good data" available from the trial authors and Roche, the maker of Tamiflu, the study authors said.

This meant the review authors couldn't verify the results of eight important trials that were never fully published. These eight trials, which were included in the previous review, were omitted from the new review.

Based on the data available to them, the authors of the new review concluded they have "no confidence in claims that Tamiflu reduces the risk of complications of influenza in otherwise healthy adults," and said the drug should not be used in routine control of seasonal flu.

Because previous evidence about Tamiflu's effects on flu complications may be unreliable, governments should establish studies to monitor the safety of Tamiflu and other neuraminidase inhibitors, said review leader Chris Del Marr, a professor at Bond University in Australia, and colleagues.

The review findings call into question "not only the effectiveness of oseltamivir but the whole system by which drugs are evaluated, regulated and promoted," Godlee and a BMJ colleague wrote in an accompanying editorial.

"Once a trial is completed, there needs to be ready access to the raw data behind any analyses used to license and market a drug," they said.

In response to the study, Roche officials said they "firmly believe in the robustness of the data" on Tamflu, and full access to trial data has been given to governments and regulatory authorities. The company also said it will make all study summaries of Tamiflu -- including key data -- available on a password-protected Web site, according to a BMJ news release.

The World Health Organization said Tuesday that data from countries around the world show that when given early, Tamiflu can reduce the severity of swine flu symptoms. Still, the agency recommends the drug be saved for people at risk of complications, such as pregnant women, the elderly, children, and those with chronic health problems, the Associated Press reported.

"This will not change our (Tamiflu) guidelines," said Charles Penn, a WHO antivirals expert.

Penn said that while previous studies have found that Tamiflu only offers a modest benefit, when patients with severe illness or those at risk of complications are treated early, fewer hospitalizations and deaths result, the AP said.

More information

The U.S. National Library of Medicine has more about Tamiflu.



-- Robert Preidt



SOURCE: BMJ, news release, Dec. 9, 2009; Associated Press


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... , ... SuperCloset is proud to officially launch our “Helping Veterans Grow ... and obstacles veterans’ need to overcome in order to face their life changes upon ... veteran(s) with a donated SuperCloset product based on the needs and ability of helping ...
(Date:5/28/2016)... AL (PRWEB) , ... May 28, 2016 , ... May ... US Open Martial Arts Fighting Challenge with theme event of “K Warriors” on June ... Mobile, AL 36608. , The event is sponsored and hosted by Shaolin Institute ...
(Date:5/28/2016)... ... ... a part of the city where’s it’s easy to spot the neon lights of chains ... to attract diners with a taste for real food. , On May 13, the ... Grill, an urban casual restaurant focusing on dishes made by hand with wholesome, organic ingredients ...
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., ... it has been recognized as one of the best small businesses for new dads ... one of nine small businesses providing progressive benefits to new parents on the organization’s ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... May 24, 2016 Cirujanos holandeses ... ayudar a los médicos a compartir sus mejores prácticas ... escala mundial. Profesionales médicos de Europa, África, ... apuntado a la aplicación, que combina la transmisión en ... totalmente seguro. Educación   "Imagine un ...
Breaking Medicine Technology: